Market research
BIOCON.NSE Biocon Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 677B
- P/E ratio
- 120.41
- Analyst target
- 439.05
- Dividend yield
- 0.0%
- Beta
- 0.31
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- INE376G01013
- Market cap
- 677B
- P/E ratio
- 120.41
- Analyst target
- 439.05
- Dividend yield
- 0.0%
- Beta
- 0.31
About
About Biocon Limited
Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BIOCON.NSE discussion.
5 years, 5 months ago
Biocon Limited is currently in a long term downtrend where the price is trading 5.6% below its 200 day moving average.
From a valuation standpoint, the stock is 50.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 7.2.
Biocon Limited's total revenue sank by 61.0% to $19B since the same quarter in the previous year.
Its net income has dropped by 73.0% to $2B since the same quarter in the previous year.
Finally, its free cash flow fell by 57.9% to $2B since the same quarter in the previous year.
Based on the above factors, Biocon Limited gets an overall score of 0/5.